Relation Between BRAF<sup>V600E</sup> Mutation and Thyroglobulin or Clinicopathologic Characteristics of Papillary Thyroid Carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 ZHANGWei , WANGNan-peng , GAOQing-jun , ZHOUYan , DUANHai-song , ZHANGWei ,  ZHAODai-wei

Department of Thyroid Surgery, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, Guizhou Province, China;

Corresponding author：

ZHAODai-wei, Email: zhaodw@hotmail.com

Keywords：

Papillary thyroid carcinoma; BRAFV600E mutation; Thyroglobulin

DOI：

10.7507/1007-9424.20150054

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To discuss the correlation of BRAF^V600E mutation with clinicopathologic characteristics or thyroglobulin (Tg) in papillary thyroid carcinoma (PTC) and its clinical significance. Methods The BRAF^V600E mutations of 55 patients with PTC were detected by nested PCR. The relations between BRAF^V600E mutation and the clinicopathologic characteristics were analyzed. Results ①The BRAF^V600E mutations happened in 29 patients with PTC, the mutation rate was 52.7% (29/55).②The BRAF^V600E mutation rate was related with extracapsular spread, multiple lesions, regional lymph node metastasis or average Tg value > 1.0μg/L during 2 years after standardized treatment (P value was 0.01, 0.02, 0.02, 0.03, respectively), but which not related with the gender, age, tumor diameter, or TNM stage (P > 0.05). Conclusion The BRAF^V600E mutation in PTC might lead to increased tumor aggressiveness and it might be related with increased Tg value after standardized treatment.

Citation： ZHANGWei, WANGNan-peng, GAOQing-jun, ZHOUYan, DUANHai-song, ZHANGWei, ZHAODai-wei. Relation Between BRAF^V600E Mutation and Thyroglobulin or Clinicopathologic Characteristics of Papillary Thyroid Carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(2): 200-203. doi: 10.7507/1007-9424.20150054 Copy

1.	郑莹, 吴春晓, 金凡, 等.上海市区1973至2005年癌症的发病趋势.诊断学理论与实践, 2009, 8(1): 25-32.
2.	高明, 滕卫平, 刘永峰, 等.甲状腺结节和分化型甲状腺癌诊治指南.中国肿瘤临床, 2012, 39(17): 1249-1272.
3.	Ikawa S, Fukui M, Ueyama Y, et al. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol, 1988, 8(6): 2651-2654.
4.	Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab, 2005, 90(12): 6373-6379.
5.	Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab, 2004, 89(6): 2867-2872.
6.	Sapio MR, Posca D, Troncone G, et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol, 2006, 154(2): 341-348.
7.	Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene, 2004, 23(44): 7436-7440.
8.	Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab, 2003, 88(9): 4393-4397.
9.	Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892): 949-954.
10.	Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol, 2009, 27(18): 2977-2982.
11.	Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res, 2009, 15(2): 485-491.
12.	牛卫, 罗月球, 陈丽荣.甲状腺乳头状癌BRAF基因突变及表达的临床意义研究.实用肿瘤杂志, 2008, 23(6): 519-523.
13.	Puxeddu E, Moretti S. Clinical prognosis in BRAF-mutated PTC. Arq Bras Endocrinol Metabol, 2007, 51(5): 736-747.
14.	Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab, 2008, 93(10): 3943-3949.
15.	Giovanella L, Ceriani L, Ghelfo A, et al. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med, 2005, 43(8): 843-847.
16.	罗家伦, 徐慧琴, 赵学峰, 等.甲状腺球蛋白及抗甲状腺球蛋白抗体联合颈部超声在分化型甲状腺癌复发或转移灶诊断中的价值.中华临床医师杂志:电子版, 2012, 6(3): 580-583.
17.	Boi F, Baghino G, Atzeni F, et al. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab, 2006, 91(4): 1364-1369.
18.	Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res, 2009, 69(21): 8317-8325.

1. 郑莹, 吴春晓, 金凡, 等.上海市区1973至2005年癌症的发病趋势.诊断学理论与实践, 2009, 8(1): 25-32.
2. 高明, 滕卫平, 刘永峰, 等.甲状腺结节和分化型甲状腺癌诊治指南.中国肿瘤临床, 2012, 39(17): 1249-1272.
3. Ikawa S, Fukui M, Ueyama Y, et al. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol, 1988, 8(6): 2651-2654.
4. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab, 2005, 90(12): 6373-6379.
5. Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab, 2004, 89(6): 2867-2872.
6. Sapio MR, Posca D, Troncone G, et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol, 2006, 154(2): 341-348.
7. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene, 2004, 23(44): 7436-7440.
8. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab, 2003, 88(9): 4393-4397.
9. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892): 949-954.
10. Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol, 2009, 27(18): 2977-2982.
11. Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res, 2009, 15(2): 485-491.
12. 牛卫, 罗月球, 陈丽荣.甲状腺乳头状癌BRAF基因突变及表达的临床意义研究.实用肿瘤杂志, 2008, 23(6): 519-523.
13. Puxeddu E, Moretti S. Clinical prognosis in BRAF-mutated PTC. Arq Bras Endocrinol Metabol, 2007, 51(5): 736-747.
14. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab, 2008, 93(10): 3943-3949.
15. Giovanella L, Ceriani L, Ghelfo A, et al. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med, 2005, 43(8): 843-847.
16. 罗家伦, 徐慧琴, 赵学峰, 等.甲状腺球蛋白及抗甲状腺球蛋白抗体联合颈部超声在分化型甲状腺癌复发或转移灶诊断中的价值.中华临床医师杂志:电子版, 2012, 6(3): 580-583.
17. Boi F, Baghino G, Atzeni F, et al. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab, 2006, 91(4): 1364-1369.
18. Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res, 2009, 69(21): 8317-8325.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Relation Between BRAF^V600E Mutation and Thyroglobulin or Clinicopathologic Characteristics of Papillary Thyroid Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Relation Between BRAFV600E Mutation and Thyroglobulin or Clinicopathologic Characteristics of Papillary Thyroid Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

Relation Between BRAF^V600E Mutation and Thyroglobulin or Clinicopathologic Characteristics of Papillary Thyroid Carcinoma